68 related articles for article (PubMed ID: 3323023)
1. Antipsychotic effects of verapamil in schizophrenia.
Price WA
Hillside J Clin Psychiatry; 1987; 9(2):225-30. PubMed ID: 3323023
[TBL] [Abstract][Full Text] [Related]
2. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
Akhondzadeh S; Safarcherati A; Amini H
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
[TBL] [Abstract][Full Text] [Related]
3. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial.
Akhondzadeh S; Nejatisafa AA; Amini H; Mohammadi MR; Larijani B; Kashani L; Raisi F; Kamalipour A
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Sep; 27(6):1007-12. PubMed ID: 14499318
[TBL] [Abstract][Full Text] [Related]
4. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
5. Psychopharmacological correlates of post-psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia.
Abuzzahab FS; Zimmerman RL
J Clin Psychiatry; 1982 Mar; 43(3):105-10. PubMed ID: 7037757
[TBL] [Abstract][Full Text] [Related]
6. Amoxapine as an antipsychotic: comparative study versus haloperidol.
Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
[TBL] [Abstract][Full Text] [Related]
7. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial.
Petit M; Raniwalla J; Tweed J; Leutenegger E; Dollfus S; Kelly F
Psychopharmacol Bull; 1996; 32(1):81-7. PubMed ID: 8927680
[TBL] [Abstract][Full Text] [Related]
8. Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial.
Fleischhacker WW; Barnas C; Stuppäck CH; Unterweger B; Miller C; Hinterhuber H
Psychopharmacol Bull; 1989; 25(1):97-100. PubMed ID: 2570438
[No Abstract] [Full Text] [Related]
9. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
Reschke RW
Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080
[TBL] [Abstract][Full Text] [Related]
10. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
Kane JM; Lauriello J; Laska E; Di Marino M; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
[TBL] [Abstract][Full Text] [Related]
12. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
[TBL] [Abstract][Full Text] [Related]
13. The AMDP system in international clinical trials: a double-blind comparison of fluperlapine and haloperidol.
Woggon B; Linden M; Beckmann H; Krebs E; Küfferle B; Müller-Oerlinghausen B; Pflug B; Schied HW
Psychopharmacol Bull; 1986; 22(1):47-51. PubMed ID: 2873619
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of tiospirone vs. haloperidol and thioridazine in a double-blind, placebo-controlled trial.
Borison RL; Sinha D; Haverstock S; McLarnon MC; Diamond BI
Psychopharmacol Bull; 1989; 25(2):190-3. PubMed ID: 2574893
[No Abstract] [Full Text] [Related]
15. Ethical questions raised by a proposed randomized, double-blind study involving placebo, standard drug therapy, and experimental antipsychotic drug therapy for patients with schizophrenia.
Abrams RA; Veenhuis P
Clin Res; 1986 Jan; 34(1):6-9. PubMed ID: 2873917
[No Abstract] [Full Text] [Related]
16. Use of verapamil to treat negative symptoms in schizophrenia.
Price WA; Pascarzi GA
J Clin Psychopharmacol; 1987 Oct; 7(5):357. PubMed ID: 3680609
[No Abstract] [Full Text] [Related]
17. Centbutindole vs trifluoperazine: a double-blind controlled clinical study in acute schizophrenia.
Doongaji DR; Satoskar RS; Sheth AS; Apte JS; Desai AB; Shah BR
J Postgrad Med; 1989 Jan; 35(1):3-8. PubMed ID: 2685263
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of the therapeutic effects between haloperidol and insulin coma in schizophrenia and optimal blood levels of haloperidol].
Shu L
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1987 Feb; 20(1):43-8. PubMed ID: 3304870
[No Abstract] [Full Text] [Related]
19. A negative, double-blind, placebo-controlled, clinical trial of verapamil in chronic schizophrenia.
Grebb JA; Shelton RC; Taylor EH; Bigelow LB
Biol Psychiatry; 1986 Jun; 21(7):691-4. PubMed ID: 3518822
[No Abstract] [Full Text] [Related]
20. A controlled double-blind comparison between loxapine and haloperidol in acute newly hospitalized schizophrenic patients.
Paprocki J; Barcala Peixoto MP; Andrade NM
Psychopharmacol Bull; 1976 Apr; 12(2):32-4. PubMed ID: 769026
[No Abstract] [Full Text] [Related]
[Next] [New Search]
